EP0991443A1 - Inhalateur - Google Patents

Inhalateur

Info

Publication number
EP0991443A1
EP0991443A1 EP97928435A EP97928435A EP0991443A1 EP 0991443 A1 EP0991443 A1 EP 0991443A1 EP 97928435 A EP97928435 A EP 97928435A EP 97928435 A EP97928435 A EP 97928435A EP 0991443 A1 EP0991443 A1 EP 0991443A1
Authority
EP
European Patent Office
Prior art keywords
button
capsule
button member
housing
disposable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97928435A
Other languages
German (de)
English (en)
Inventor
Marco Cecchini
Francesco Merante
Ivo E. Pera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0991443A1 publication Critical patent/EP0991443A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Definitions

  • the present invention relates generally to inhalers, and more particularly to a monodose disposable inhaling device. Background art
  • the lung is considered to be one of the more effective, noninvasive routes of administration to the systemic circulation.
  • a number of powdered medications can be used to treat a variety of conditions that accompany many different diseases. Conditions requiring an inhaling device, particularly in such therapy where it can be administered to a patient on a program of home care, include (1) infection, (2) mucosal edema, (3) tenacious secretions, (4) foam buildup, (5) bronchospasms, and (6) loss of compliance. Furthermore, infections are often accompanied with one or more of these identified conditions. Inhalation of powdered medicaments by inertial devices is a complex and important issue. Conventional dry powder inhalers deliver their dose of drug on the breath of the patient.
  • the conventional dry powder inhaler has a characteristic resistance to laden airfl-ow rate, therefore, the pressure drop, and by inference the volumetric flow through these systems, will vary.
  • the general properties given rise to errors in these inhalers when dispensing proper medicaments are specific directional and velocity characteristics, includine, but not limited to, instability and concentration of the mass of particles administered in a unit volume of air. Additionally, in a definitive clinical setting the patient's inspiratory flow can vary significantly.
  • Several devices have been developed for the administration of micronized powders of relatively potent drugs.
  • the Norisodrine Sulfate Aerohaler Cartridge (Abbott) is an example of such devices. With this device the inhalation by the patient causes a small ball to strike a cartridge containing the necessary drug.
  • Other devices include the SPINHALER (Fisons) and the TURBOHALER (Astra) , which are propeller-driven devices designed to deposit a mixture of lactose and micronized cromolyn sodium into the lung.
  • Additional devices includes the ROTAHALER, BECLODISK, DISKHALER, VENTODISK AND DISKUS, all developed by the Glaxo company, and are used for the administration of powdered drugs to the respiratore tract. These devices have proven to cumbersome, complicated and relatively expensive. As such, the single use of these devices is not practical.
  • Powdered medicaments administered by inhalation are not frequently used for delivery into the systemic circulation, due to various factors that contribute to erratic or difficulto-achieve blood levels. Whether or not the powder drugs reaches and is retained in the pulmonary alveoli depends critically upon particle size (particles greater than 1 micromillimeter (um) in diameter tend to settle in the bronchioles and bronchi, whereas particles less than .6 micromillimeter (um) fail to settle and are mainly exhaled) . With pharmacopeia, particle size is of major importance in the administration of this type of preparation.
  • the present invention generally provides a monodose disposable inhaling device for dispensing a single dose of powdered medicaments into the respiratore tract.
  • the inhaling device generally consists of a body member having a delivery portion and a housing portion, a button member, a spring member and a spring and capsule support member.
  • the button member includes a post member having a sharp pointed puncturing end.
  • screen means can be disposed within the body member at the intersection of the delivery portion and the housing portion.
  • the patient or user When the patient or user requires the desired medicaments, he or she places the outer end of the delivery portion into his or her mouth and presses the button member downward.
  • the user breathes-in while pressing the button member downward.
  • the pressing of the button member downward causes a sharp pointed end of the post member to extend through the capsule and into the powder receiving area, thus, puncturing the capsule to release the stored dry powdered medicament into the powder receiving area.
  • the breathing-in by the user causes the released medicaments to relatively quickly enter the delivery portion and ultimately the lungs of the patient.
  • the screen means is sized to prevent the capsule member or pieces of the capsule member from entering into the delivery portion and possibly the user.
  • the user preferably disposes of the device after its single use.
  • the user is not bothered with removing the punctured capsule member and replacing it with a new capsule member having the desired medicaments inside. Further, the user does not have to worry about properly cleaning the inhaling device after each use.
  • the present invention inhaler follows the logic of a single and exact dose of medicine disposed with, in a conventional capsule member, including, but not limited to, a small aluminum foil bag.
  • the capsule member, containing the medicine therein is disposed within the housing portion of the body member, which is preferably constructed from plastic, or other appropriate material which can also be biodegradable, and suitable for inhalation, due to its conformation.
  • the medicine disposed within the bag is made available to the patient by the simple pressing of a button member while the patient simultaneously breathes inward. The pressing of the button member by the patient causes a post member associated with the button to puncture the bag which delivers the powdered medicine to the central lumen (lower area of housing portion) for delivery.
  • the medicine is then subject to a vortex of air created by the particular conformation of the internal channel (defined by the housing portion and button member) of the inhaler, thus ensuring an adequate dispersion and micronization of the powder.
  • the delivery channel (delivery portion of the body member) can be somewhat flare outward or tapered, to ensure a correct opening of the patient's lips.
  • the entrance nozzle of the air is supplied by a special valve which ensures the one way flow of the air and eliminates the possibility of mistaken actions before or duringthe inhalation of the powdered medicament.
  • the present invention inhaler greatly scatters the powder medicament, as compared to prior art inhalers, leaving a relatively very low rate of powdered drug remaining in the inhaler.
  • the present invention inhaler can be manufactured by means of injection moldings well known in the art, thereby affecting substantial cost reduction in manufacturing the device without adversely affecting the medicament administration inhalation.
  • the energy of air flowing through the inhaler is utilized to deliver into the lining a single dose of powdered medicaments
  • This charge of energy is delivered quickly, relatively shortly after inhalation begins, and finds its way to its desired location respiratore tract) -
  • the inhaler itself and the body passages first receiving the stream of air are thoroughly swept and scavenged with pure air during a major portion of the breathing-in process
  • Administration of the medicament in this fashion contributes to deep penetration of the medicament, and eliminates the need to pulverize or micronize the medicament into true smoke.
  • the use of larger particle of medicament tends to increase the reliability with which a uniform fraction of the medicament will pass through the body passages first receiving the air stream, without getting caught on the moist walls of the body passage.
  • the drug can be delivered into the alveoli of the lungs.
  • the alveolar and vascular epithelial membranes are quite permearle and blood flow is abundant. Thus a relatively very large surface for adsorption is provided and use of the present invention allows for virtually rapid absorption of the powdered medicantents.
  • the monodose disposable inhaling device can be used in respiratore therapy, as well as for other diseases, through the topical administration of medications through the mucosal linings of the tracheo-bronchial tree and the lungs.
  • the monodose disposable inhaling device of the present invention allows the user to effectively and smoothly inhale the powdered medicaments into the pulmonary tract, by the simple inspiration of air.
  • the use of the monodose disposable inhaling device of the present invention through the respiratore tract may provide an efficient means of administering dry powder medicaments such as vasoconstrictors, antihistaminics, antispamodics, antipeptics, antibronchiolitis, B2-stimulants-corticosteroids, antivirals, antifungals, antioxidants, antileukotrienes, antiallergens, antibiotics, human proteins, peptides, etc. These medicaments will generally require a smaller dosage then necessary if such medicaments were given systemically.
  • dry powder medicaments such as vasoconstrictors, antihistaminics, antispamodics, antipeptics, antibronchiolitis, B2-stimulants-corticosteroids, antivirals, antifungals, antioxidants, antileukotrienes, antiallergens, antibiotics, human proteins, peptides, etc.
  • medicaments will generally require a smaller dosage then necessary if such medicaments were given systemically.
  • the present invention can be utilized to properly dispense powdered medicinals, as well as for other applications with potentially enormous benefits which can be hypothesized for other substances such as cortisteroids, for vaccines which are curreritly being developed for the treatment of allergies, for antibiotics used in cyclical and prophylactic treatment particularly of chronic bronchitis and chronic bronchial pathologies with recurrent infections (mucoviscidosis, immune deficiency syndrome, AIDS, etc.).
  • the present invention also provides for reduction of oral mycosis, commonly associated with spray devices, which deposit the medicinals in the area of the tongue and oropharynx, due to the backwards direction of the spray itself.
  • the present mvention eliminates such as it is disposable, thus, providing for optimal micronisation.
  • Use of the inhaler of che present invention allows for dispensing of powdered medicaments available in the form of fine powders which allows for a high concentration of the medicament to reach the respiratore tract for effective therapeutic effect.
  • the present irivention is relatively easy to operate, patients are less prone to become frustrated when taking their prescribed medicants, resulting in a greater percentage of patients completing the therapy and receiving proper dosages, as well as reducing hospital time required for receiving the therapy or instructions on how to self -administer the prescribed medicants.
  • the present invention can be utilized with antibiotics, steroids and other difficult soluble compounds. Problems associated with the formulation of these drugs include agglomeration, caking, particle-size growth and often clogging, which are eliminated by the use of the present invention.
  • the invention makes possible to dispense any type of powdered drugs which are at all times completely under the control of the user.
  • the present invention inhaler provides a simple and convenient means of dispensing powdered drugs, and is capable of extremely wide applications.
  • Inhaler 10 generally consists of a body member 20 having a delivery portion 22 and a housing portion 24, a button member 80, a spring member 70 and a spring and capsule support member 60. Additionally, a screen means 50 can be disposed within body member 20 at the intersection of delivery portion 22 and housing portion 24. Screen means 50 can be associate with an outer grid member, as is known in the art. As stated above, body member 20 includes a delivery portion 22 and a housing portion 24. Preferably, delivery portion 22 and housing portion 24 are constructed integral.
  • Delivery portion 22 has a first open end 32 and a second open end 34.
  • a medicant passageway 28 is defined by delivery portion 22 extending from first end 32 to second end 34.
  • delivery portion 22 and, thus, passageway 28, taper outward from second end 34 to first end 32, to ensure a correct opening of the patientls lips.
  • Housing portion 24 includes a bottom section defining a powder receiving area 36 and a top section defining a portion of a spring receiving area 38. Housing portion 24 also includes an open top end 40. The bottom section orhousing portion 24 defines an aperture to allow passageway 28 of delivery portion 22 to communicate with housing portion 24 at powder receiving area 36.
  • a screen means 50 having a grill member 52 can be disposed within the aperture defined by the bottom section of housing portion 24. In lieu of screen means 50, a plurality of apertures can be formed in housing portion adjacent the intersection of the second end of delivery portion 22 and housing portion 24, to allow delivery passageway 28 to communicate with powder receiving area 36.
  • Housing portion 24 also includes a wall member 26 having an outer slot or groove 30 which can extend upward and deeper within wall member 26 from its first end 33 to its second end 35 to define a button retaining means at second end 35.
  • a button retaining means can be a wall member formed at second end 35 by the increase in depth of slot 30 from first end 33 to second end 35.
  • Wail member 2*6 also defines inner grooves or slots 42a and 42b, which extend downward from top end 40 along a substantial portion of wall member 26 to provide air entrances into powder receiving area 36.
  • Spring and capsule support member 60- includes a spring and capsule restino portion 62 having an aperture 64 extending therethrough and a positioning member 66 extending dovjnward from resting portion 62.
  • Support member 60 is disposed within housing portion 24.
  • positioning member 66 abuts the bottom of powder receiving area 36 when support member 60 is disposed within housing portion 24.
  • Resting portion 62 also defines the top of powder receiving area 36.
  • positioning member 66 should be at least slightly greater in height than a capsule 100 or 105 containing the powdered medicament (s) , to assure that capsule 100 or 105 ( Figured 5a-5d) properly depends from support member 60 into powder receiving area 36.
  • At least one protrusion 68 depends outward from resting portion 62.
  • protrusions 68 are aligned within inner groove 42a and travel along groove 42a until positioning member 66 abuts the bottom of powder receiving area 36.
  • Protrusions 68 are preferably disposed adjacent the center of positioning member 66 to ensure proper placement of support member 60 within housing port ion 24. Additionally, protrusions 68 also help to prevent the shifting or horizontal movement of support member 60 during the operation of inhaler 10, which could also block or partially block the communication between delivery passageway 28 and powder receiving area 36.
  • two protrusions 68 are provided. Though protrusions 68 are disposed within groove 42a, sufficient area is still provided for air to travel into receiving area 36 through groove 42a.
  • an inner ledge member (not shown), can be formed integral within wall member 26.
  • the inner ledge member thus, defines the top of powder receiving area 36 and the bottom of spring receiving area 38 and also provides the resting area for spring means 70 and capsule 100 or 105.
  • the ledge member should be formed high enough along wall member 26 to allow sufficient room in powder receiving area 36 for the receipt of various sizes of capsules. A pair of gaps in the ledge member should also be provided to allow grooves 42a and 42b to continue into receiving area 36.
  • a capsule member such as, but not limited to, either capsule 100 or 105, is properly disposed within housing portion 24.
  • Capsule 100 or 105 can be a conventional capsule and is preferably constructed from aluminum foil or a plastic film.
  • Medicament storing area 104 or 108 of capsule 100 or 105, respectively, is inserted through aperture 64 of support member 60 until respective capsule ledge member 102 or 106 abuts resting area 62.
  • capsule 100 or 105 is properly positioned within housing portion 24 and spring means 70 is disposed within housing portion within spring receiving area 38.
  • the desired dry powder medicament is stored within capsule 100 or 105 within storing area 104 or 108, respectively.
  • the powder medicament will be of a particle size in accordance with the range descrive above.
  • Spring means can be a conventional spring, and has a first end 72 which abuts capsule 100 or 105 and a second end 74 which abuts an inner portion of button member 80, also discussed in detail below.
  • button member 80 is attached to housing portion 24 by the mating of at least one ear member 94 with corresponding grooves 30 in wall member 26.
  • ear member 94 Preferably, two ear members 94 and two corresponding grooves are provided.
  • a protrusion 96 depends inward from ear member 94.
  • Ear members 94 can be formed by creating slots 95a and 95b within wall member 82 of button member 80.
  • Button member 80 includes a closed top end 84 and an open bottom end 86. Wall member 82 and closed top end 84 define the top section of spring receiving area 38.
  • the inner diameter of button member 80 is slightly larger then the outer diameter of housing portion 24, for the receipt of a top section of housing portion 24 within button member 80 when button member 80 is attached to housing portion 24.
  • Button member 80 also defines a cutout 88 at a bottom area of wall member 82 which is sized to receipt a portion of delivery member 22 when button member is pressed, discusse in detail below. Furthermore, at least one, and preferably two apertures 90 extending through wall member 82 near top end 84 can be provided. Apertures 90 provide turbulence and increase velocity during the depression of button member 80, discusse further below. Thus, holes 90 improve the turbulent flow of air inside the chamber (housing portion 24) of body member 20. This improved turbulent flow of air is also provided by grooves 42a and 42b disposed within wall member 26. Button member 80 can also be provided with spring retaining members 98. End 72 of spring member 70 can be retained between retaining member 98, to prevent spring member 70 from shifting out of position.
  • end 72 of spring 70 can be attached to button member 80 prior to disposing spring 70 into housing portion 24. After end 72 is attached to button member 80, end 74 of spring member 70 is inserted within housing portion 24 and button member 80 is attached to housing portion 24 relatively, quick thereafter, if not simultaneously.
  • Button member 80 is also provided with a post member 92 protruding downward within the top of spring receiving area 38 defined by wall member 82 and top end 84.
  • post 92 is formed integral with button member 80 at the inner surface of closed top end 84.
  • Post member 92 includes a sharp pointed end 93 for puncturing a capsule, such as capsule 100 or 105, disposed within powder receiving area 36 during the use of inhaler 10, discusse below.
  • Post member 92 also extends through spring means 70 when button member 80 is properly attached to housing portion 24.
  • Spring means 70 maintains button member 80 in a first upward position to help prevent post member 92 from inadvertently puncturing capsule 100 or 105 containing the powdered medicamene which is disposed within powder receiving area 36 of housing portion 24, prior to the pressing of button member 80.
  • protrusions 96 abut second end 35 of groove 30, which acts as a stop means, and maintains the attachment of button member 80 to housing portion 24.
  • capsule member 100 or 105 having the desired medicaments (preferably in a dry powder form) stored within area 104 or 108 of capsule 100 or 105, respectively, is disposed within powder receiving area 36 as discussed above. WTien the patient or user requires the desired medicaments, he or she places end 32 of delivery portion 22 in his or her mouth and presses button member 80 downward. Preferably, the user breathes-in while pressing button member 80 downward. The pressing of button member 80 downward provides a turbulent air flow within housing portion 24 and causes pointed end 93 to extend through capsule 100 or 105 and aperture 64 of support member 60 and into powder receiving area 36, puncturing capsule member 100 or 105 to release the stored dry powdered medicament into powder receiving area 36.
  • Screen means 50 is sized to prevent the capsule member or pieces of the capsule member from entering into passageway 28 and possibly the user.
  • button member 80 is depressed until cutout 88 abuts its adjacent portion of delivery portion 22. This abutted relationship also defines the maximum downward position button member 80 can be pressed.
  • An inhaling device 10 is relatively inexpensive, the user preferably disposes of device 10 after its single use.
  • the user is not bothered with removing the punctured capsule member and replacing it with a new capsule member having the desired medicaments inside. Further, the user does not have to worry about properly cleaning inhaling device 10 after each use.
  • inhaling device 10 can be reused, as button member 80 can be removably attached to housing portion 24.
  • button member 80 and spring means 70 are removed.
  • the punctured capsule is removed and if support member 60 is provided it can also be removed for easier cleaning of inhaler 10.
  • support 60 is once again properly disposed within housing portion 24, a new capsule member is then disposed, as descrive above, preferably after device 10 has been properly cleaned.
  • Spring means 70 and button member 80 are then properly positioned and reattached.
  • device 10 is instructed from plastic, however, other conventional materials, though not preferred, are within the scope of the invention. Additionally, it is also preferred, though not required, that body member 20, support member 60 and button member 80 be transparent. In such embodiment, it will be readily apparent to the user wheter his or her breathing actions have removed all of the released dry powder of medicaments from receiving area 36. It is also preferred that housing portion 24, support member 60 and button member 80 be substantially circular in shape. Figures 6a and 6b illustrate an inhaling device having alternative body member embodiment 120.
  • delivery portion 122 is similar to delivery portion 22, but housing portion 124 is constructed integral with delivery portion 122 at an angle, preferably from, but not limited to, forty-five (45°) to sixty (60°) degrees, instead of perpendicular, as housing portion 24 is constructed integral with delivery portion 22 for inhaling device 10.
  • Angled housing portion 124 allows for greater velocity and more speed during the releasing of the powdered medicaments, thus, allowing the powdered medicaments to reach the user quicker due to the improvement of the turbulent flow of air within housing portion 124.
  • This embodiment can be utilized with small children, elderly patients, or other individuale who may not be able to breath-in at the same strength as an healthy adult. All other parts of the inhaling device are similar to like parts for inhaling device 10.
  • FIGS 9a-9e illustrate an inhaling device 200 having an alternative embodiment for its button member.
  • inhaler 200 includes a first cover member 280 having a wall member 281.
  • Ear members 284, having respective protrusions 286 are formed by slots 287a arid 287b in wall member 281, similar to ear member 94 and protrusion 96.
  • Apertures 282 are provided within wall member 281, similar to apertures 90.
  • An additional aperture 288 is provided in top end 289 which is sized to receive a pressing portion 292 of button 290, discussed below.
  • First cover member 280 can also be provided with a ledge 283.
  • Button member 290 includes pressing portion 292, lip or intercediate portion 293 and a post member 294 having a pointed end 295 which depends downward from lip portion 293.
  • Post member 294 is similar to post 92.
  • the diameter of pressing portion Z-92 is slightly smaller than the diameter of aperture 288.
  • a protective cover member 296 can be provided and is attached to first cover member 280 to prevent inadvertent pressing of button member 292.
  • the inner diameter of second cover member 296 is slightly larger than the diameter of the inserted portion of first cover member 280.
  • a lower end 298 of second cover member 296 rest upon ledge 283.
  • Body member includes a delivery portion 310 communicating with a housing portion 324 and a button member 380.
  • a screen means can also be provided.
  • delivery portion 310 and housing portion 324 are constructed integral.
  • Delivery portion 310 includes an open first end and a second end.
  • Delivery portion 310 also defines a passageway extending from its first end to its secorid end Housing portion 324 includes a powder receiving area 336.
  • grooves 42a and 42b and apertures 90 are eliminated and an air entrance way into powder receiving area 336 is provided by a flanged portion 340 associated with the bottom of housing portion 324.
  • Flange portion 340 includes an aperture 342 which allows ambient air to enter within powder receiving area 336.
  • Flanged portion 340 can be angled to facilitate air flow into powder receiving area 336 during use of inhaling device 300.
  • the addition of flanged portion 340, and the elimination of grooves 42a and 42b and apertures 90, this embodiment of the present invention is structurally similar to any of the other embodiments, described above, and also functions similarly, as well as being operated by the user similarly. All of the embodiments of the present invention provide for a proper mixture of air with the medication during the transmission of the medication to the breathing portions of the body, thereby increasing the efficiency of the medicamentna mixture.
  • the various embodiments of the monodose disposable inhaling device of the present invention efficiently dispenses powdered medicinals through the respiratory tract, which provides the following advantages: (1) easy to use, relieving the patient of mental tension and anxiety regarding the mode of administration and the immediate check of the completed operation;
  • inhaling device is, preferably, discarded following the administration of the contained drug, thus, avoiding hygiene problems of multidose devices which after the first time of their use can be contaminated with bacterials and are easily soiled and subject to blockage;
  • Figure 1 is an exploded perspective view of a first embodiment of the present invention
  • Figure 2 is a front sectional view of the invention shown in Figure 1; • Figure 3a ia a top view of a first embodiment body member of the present invention;
  • Figure 3b is a front elevational view of the body member of Figure 3a;
  • Figure 3c is a front sectional view of the body member of Figure 3 a;
  • Figure 4a is a side elevational view of a button member of the present invention
  • Figure 4b is a front elevational view of the button member of Figure 4a;
  • Figure 4c is a side sectional view of the button member of Figure 4a;
  • Figure 5a is a front elevational view of a first embodiment capsule member in accordance with the present invention.
  • Figure 5b is a top view of the capsule member of Figure 5a; • Figure 5c is a front elevational view of a second embodiment capsule member in accordance with the present invention;
  • Figure 5d is a top view of the capsule member of Figure 5 c;
  • Figure 6a is a front sectional view of a first alternative body member embodiment of the present invention
  • Figure 6b is a top view of the body member of Figure 6a;
  • Figure 7 is a front sectional view of a second alternative body member embodiment of the present invention.
  • Figure 8 is a front sectional view of a button member used in conjunction with the body member illustrato in Figure 7;
  • Figure 9a is a front sectional view of an alternative button member embodiment for the present invention;
  • Figure 9b is a front sectional view of an alternative button member embodiment for the present invention also including a protective cover member;
  • Figure 9c is a front sectional view of a first cover member of the alternative button embodiment illustrate in either Figure 9a or Figure 9b;
  • Figure 9d is a front sectional view of the protective cover member of the alternative button embodiment illustrate in Figure 9b;
  • Figure 9e is front elevational view of the button and puncturing member of the alternative button embodiment illustrate in either Figure 9a or Figure 9b.

Abstract

La présente invention concerne un inhalateur monodose jetable convenant pour l'administration d'un médicament via les voies respiratoires. Cet inhalateur permet une administration plus commode des médicaments secs, et notamment des médicaments en poudre, particulièrement pour ce qui est de la précision du dosage et de la précision du point d'application du médicament. Selon une réalisation, l'inhalateur se compose essentiellement d'un corps pourvu d'un distributeur intégré à un carter, d'un bouton, d'un ressort, et d'un support à ressort et capsule. En outre, un élément écran peut être disposé dans le corps à l'intersection du distributeur avec le carter.
EP97928435A 1997-06-23 1997-06-23 Inhalateur Withdrawn EP0991443A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT1997/000146 WO1998058695A1 (fr) 1997-06-23 1997-06-23 Inhalateur

Publications (1)

Publication Number Publication Date
EP0991443A1 true EP0991443A1 (fr) 2000-04-12

Family

ID=11332723

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97928435A Withdrawn EP0991443A1 (fr) 1997-06-23 1997-06-23 Inhalateur

Country Status (3)

Country Link
EP (1) EP0991443A1 (fr)
AU (1) AU3273497A (fr)
WO (1) WO1998058695A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE517227C2 (sv) * 2000-09-25 2002-05-14 Microdrug Ag Inhalator för torrt pulver med folieskärare
GB0215904D0 (en) 2002-07-09 2002-08-21 Team Holdings Uk Ltd Drug delivery system and method
EP1488819A1 (fr) 2003-06-16 2004-12-22 Rijksuniversiteit te Groningen Inhalateur de poudre sèche et procédé d'inhalation pulmonaire de poudre sèche
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2001535A1 (fr) * 2006-03-21 2008-12-17 Bang & Olufsen Medicom A/S Passage d'écoulement d'inhalateur
ES2394589T3 (es) 2007-12-14 2013-02-04 Aerodesigns, Inc Suministro de productos alimenticios transformables en aerosol
WO2017079397A1 (fr) * 2015-11-05 2017-05-11 Otitopic Inc. Dispositif d'inhalation de poudre sèche

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2224175B1 (fr) * 1973-04-04 1978-04-14 Isf Spa
IT1016489B (it) * 1974-03-18 1977-05-30 Isf Spa Inalatore
GB8314308D0 (en) * 1983-05-24 1983-06-29 Matburn Holdings Ltd Medical administration devices
EP0528764B1 (fr) * 1991-08-16 1996-06-12 Sandoz Ltd. Inhalateur pour administrer des substances en poudre
US5415162A (en) * 1994-01-18 1995-05-16 Glaxo Inc. Multi-dose dry powder inhalation device

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9858695A1 *

Also Published As

Publication number Publication date
WO1998058695A1 (fr) 1998-12-30
AU3273497A (en) 1999-01-04

Similar Documents

Publication Publication Date Title
US5669378A (en) Inhaling device
JP3209539B2 (ja) 粉末薬物の投与器具
US8397713B2 (en) Mouthpiece and flow rate controller for intrapulmonary delivery devices
US4926852A (en) Medication delivery system phase one
US7025059B2 (en) Inhaling device for dispersing powdered medicaments contained in a capsule through the respiratory tract
ES2305057T3 (es) Dispositivo para la administracion de farmacos orales.
RU2141849C1 (ru) Устройство для распыления лекарственного средства в форме порошка
ES2872350T3 (es) Polvos farmacéuticos de dosis baja para inhalación
AU2002255808B2 (en) Inhalation device and method
JP4497730B2 (ja) 複合薬剤用の粉末吸入器
ES2284226T3 (es) Dispositivo para proporcionar medicamentos en aerosol.
CA1327299C (fr) Systemes d'administration de medicaments - phase ii
JP2927464B2 (ja) エアゾール装置
KR20090005379A (ko) 간소형 흡입기
JP2001511402A (ja) 薬剤のデリバリの引き金となる吸入活性化流れ分割手段を有する乾燥粉末薬剤吸入器
JPH0141343B2 (fr)
JPS6017543B2 (ja) 薬物吸入装置
JP2001527442A (ja) ハロセラピーの投与方法
WO1998058695A1 (fr) Inhalateur
US8794232B2 (en) Disposable monodose inhaler for powdered medicaments
EP1177805A1 (fr) Inhalateur de poudre

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE

17Q First examination report despatched

Effective date: 20020905

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030103